Mangoceuticals (MGRX) Registration Filing summary

Company overview and business model

• Operates a telehealth platform focused on men's wellness, offering ED, hair loss, hormone, and weight management products, plus an FDA-approved oral testosterone therapy.

• Products are sold online via a proprietary portal, with fulfillment by a related-party pharmacy licensed in 49 states and DC.

• Compounded products are formulated as sublingual tablets and are not FDA-approved, relying on Section 503A exemptions.

• Recent expansion includes licensing plant-based skin care IP and acquiring patents for respiratory illness prevention and mushroom-based nutraceuticals.

Financial performance and metrics

• For the nine months ended September 30, 2025: revenue was $361,661, down from $510,626 in the prior year period.

• Net loss for the nine months ended September 30, 2025 was $17.9 million, compared to $6.8 million in the prior year.

• As of September 30, 2025: cash was $481,281, total assets $16.5 million, total liabilities $804,275, and accumulated deficit $37.9 million.

• Recurring net losses and negative cash flows raise substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Proceeds from warrant exercises will be used for general working capital.

• No proceeds from the resale of shares by selling stockholders; company bears registration expenses.

• Recent capital raised through preferred stock, warrant exercises, and equity lines; significant dilution risk exists.